Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone

Thorax

Volumn 69, Issue 4, 2014, Pages 312-319

  Bateman, Eric D ^a   O'Byrne, Paul M ^b   Busse, William W ^c   Lötvall, Jan ^d   Bleecker, Eugene R ^e   Andersen, Leslie ^f   Jacques, Loretta ^g   Frith, Lucy ^g   Lim, Jessica ^g   Woodcock, Ashley ^h  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

^f GLAXOSMITHKLINE   (United States)

^g GLAXOSMITHKLINE   (United Kingdom)

^h UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE FUROATE; FLUTICASONE FUROATE PLUS VILANTEROL;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY POWDER INHALER; EVENING DOSAGE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONCARDIAC CHEST PAIN; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PLEURISY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SCHOOL CHILD; TACHYCARDIA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ASTHMA; ASTHMA PHARMACOLOGY;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; BENZYL ALCOHOLS; CHILD; CHLOROBENZENES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HUMANS; MALE; RISK; TREATMENT OUTCOME;

EID: 84895925189     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2013-203600     Document Type: Article

References (32)

1. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. Updated 2011. http://www.ginasthma.org/uploads/users/ files/GINA-Report-2011.pdf (accessed 8 Jul 2013).
2. O'Byrne PM, Naya IP, Kallen A, et al. Increasing doses of inhaled corticosteroids compared to adding long-acting β2-agonists in achieving asthma control. Chest 2008;134:1192-9.
3. Shapiro G, Lumry W, Wolfe J, et al. Combined salmeterol 50 mg and fluticasone propionate 250 mg in the Diskus device for the treatment of asthma. Am J Respir Crit Care Med 2000;161:527-34. (Pubitemid 30129463)
4. Nelson HS, Weiss ST, Bleecker ER, et al. The salmeterol multicenter asthma research trial. Chest 2006;129:15-26.
5. Salpeter SR, Buckley NS, Ormiston TM, et al. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 2006;144:904-12. (Pubitemid 46768131)
6. Bateman ED, Nelson H, Bousquet J, et al. Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. Ann Intern Med 2008;149:33-42.
7. Sears MR, Ottosson A, Radner F, et al. Long-acting β-agonists: a review of formoterol safety data from asthma clinical trials. Eur Respir J 2009;33:21-32.
8. Jaeschke R, O'Byrne PM, Mejza F, et al. The safety of long-acting β-agonists among patients with asthma using inhaled corticosteroids: systematic review and metaanalysis. Am J Respir Crit Care Med 2008;178:1009-16.
9. Chowdhury BA, Seymour SM, Levenson MS. Assessing the safety of adding LABAs to inhaled corticosteroids for treating asthma. N Engl J Med 2011;364:2473-5.
10. Biggadike K, Bledsoe RK, Hassell AM, et al. X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain. J Med Chem 2008;51:3349-52. (Pubitemid 351874991)
11. Salter M, Biggadike K, Matthews JL, et al. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol Lung Cell Mol Physiol 2007;293: L660-7. (Pubitemid 47358828)
12. Bateman ED, Bleecker ER, Lötvall J, et al. Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial. Respir Med 2012;106:642-50.
13. Bleecker ER, Lötvall J, O'Byrne PM, et al. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma. Eur Respir J 2012;40(Suppl 56):P2091.
14. Busse WW, Bleecker ER, Bateman ED, et al. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. Thorax 2012;67:35-41.
15. Boscia JA, Pudi KK, Zvarich MT, et al. Effect of once-daily fluticasone furoate/ vilanterol on 24-hour pulmonary function in patients with COPD: a randomized, three-way, incomplete block, crossover study. Clin Ther 2012;34:1655-66.e5.
16. Lötvall J, Bakke P, Bjermer L, et al. Efficacy and safety of 4 weeks' treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial. BMJ Open 2012;2:e000370.
17. Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/ European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009;180:59-99.
18. Bateman ED, O'Byrne PM, Busse WW, et al. Effect of fluticasone furoate (FF)/ vilanterol (VI) once daily (OD) on risk of severe exacerbations in asthma. Eur Respir J 2012;40(Suppl 56):P1788.
19. National Institutes for Health (NIH). Guidelines for the diagnosis and management of asthma (EPR-3) 2007. NIH publication no 08-4051. NIH Heart, Lung and Blood Institute, 2007.
20. Irwin RS, Richardson ND. Side effects with inhaled corticosteroids: the physician's perception. Chest 2006;130(Suppl 1):41S-53S. (Pubitemid 44107235)
21. Pauwels RA, Löfdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997;337:1405-11.
22. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control Study. Am J Respir Crit Care Med 2004;170:836-44. (Pubitemid 39346477)
23. Rodrigo GJ, Castro-Rodríguez JA. Safety of long-acting β agonists for the treatment of asthma: clearing the air. Thorax 2012;67:342-9.
24. Masoli M, Weatherall M, Holt S, et al. Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. Thorax 2005;60:730-4. (Pubitemid 41297891)
25. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001;164:1892-7.
26. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000;320:1368-73. (Pubitemid 30261116)
27. Peters SP, Prenner BM, Mezzanotte WS, et al. Long-term safety and asthma control with budesonide/formoterol versus budesonide pressurized metered-dose inhalers. Allergy Asthma Proc 2008;29:499-516.
28. Scicchitano R, Aalbers R, Ukena D, et al. Efficacy and safety of budesonide/ formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 2004;20:1403-18. (Pubitemid 39361344)
29. Kerwin E, Prazma CM, Sutton L, et al. Safety and efficacy of long-term treatment with fluticasone propionate and salmeterol via DISKUS versus fluticasone propionate alone. Clin Res Reg Aff 2011;28:14-21.
30. Katial R, Bernstein D, Prazma C, et al. Long-term treatment with fluticasone propionate (FP) and salmeterol via DISKUS (FSC) improves asthma control versus fluticasone propionate alone. Allergy Asthma Proc 2011;32:127-36.
31. Tattersfield AE, Postma DS, Barnes PJ, et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. Am J Respir Crit Care Med 1999;160:594-9. (Pubitemid 29380678)
32. Busse WW, Bleecker ER, Bateman ED, et al. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. Thorax 2011;67:35-41.